Innovent's General Biomedicine Pipeline to be Showcased at the ADA

Innovent Biologics (IVBIY) presented multiple research findings at the ADA 85th Scientific Sessions, showcasing two key drug candidates. IBI3030, a novel antibody-peptide conjugate, demonstrated significant improvements in cardiovascular risk markers through its multi-target approach combining PCSK9 inhibition with GLP-1R/GCGR/GIPR activation. Preclinical studies showed notable reductions in LDL-c, Lp(a), and body weight, with improved glucose tolerance. Additionally, three investigator-initiated studies of mazdutide, their dual GCG/GLP-1 receptor agonist, revealed superior efficacy compared to semaglutide in reducing liver fat accumulation, alleviating MASH and hepatic fibrosis, and lowering serum uric acid levels through enhanced fatty acid oxidation and metabolic regulation.

https://www.stocktitan.net/news/IVBIY/multiple-research-results-from-innovent-s-general-biomedicine-6o4nvb3qe6s9.html